Clinical Trial Update: Anti-Mesothelin Antibody Drug Conjugate Anetumab Ravtansine for Mesothelin Expressing Lung Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial of anetumab ravtansine for mesothelin-expressing lung adenocarcinoma was terminated; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Adenocarcinoma
• Lung Neoplasms

Drugs mentioned

• Anetumab Ravtansine (anetumab ravtansine)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Lung Neoplasms | Phase 2 | Status: TERMINATED | Results posted: 2019-05-21